The Wnt/β-catenin signaling pathway plays a critical role in neuronal development, synaptic plasticity, and cellular homeostasis. Dysregulation of this pathway has been implicated in multiple neurodegenerative diseases, including the 4R-tauopathies: Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Argyrophilic Grain Disease (AGD), Globular Glial Tauopathy (GGT), and FTDP-17 (MAPT mutations). This analysis compares how Wnt signaling, and related pathways including GSK3β, YAP/TAZ, and the Hippo pathway, differ across these diseases.
The canonical Wnt/β-catenin pathway is initiated by Wnt ligand binding to Frizzled receptors and LRP5/6 co-receptors. This prevents β-catenin degradation, allowing it to accumulate and translocate to the nucleus where it interacts with TCF/LEF transcription factors to regulate target genes[@clevers2012].
In 4R-tauopathies, Wnt/β-catenin signaling shows disease-specific alterations:
| Disease | Wnt Pathway Activity | Key Findings |
|---------|-----------------|-------------|
| PSP | Reduced | Decreased nuclear β-catenin in basal ganglia[@marchetti2020] |
| CBD | Reduced | Wnt ligand downregulation in motor cortex |
| AGD | Variable | Region-specific changes in entorhinal cortex |
| GGT | Reduced | Oligodendrocyte lineage affected |
| FTDP-17 | Variable | Mutation-dependent effects |
The Wnt/β-catenin signaling pathway plays a critical role in neuronal development, synaptic plasticity, and cellular homeostasis. Dysregulation of this pathway has been implicated in multiple neurodegenerative diseases, including the 4R-tauopathies: Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Argyrophilic Grain Disease (AGD), Globular Glial Tauopathy (GGT), and FTDP-17 (MAPT mutations). This analysis compares how Wnt signaling, and related pathways including GSK3β, YAP/TAZ, and the Hippo pathway, differ across these diseases.
The canonical Wnt/β-catenin pathway is initiated by Wnt ligand binding to Frizzled receptors and LRP5/6 co-receptors. This prevents β-catenin degradation, allowing it to accumulate and translocate to the nucleus where it interacts with TCF/LEF transcription factors to regulate target genes[@clevers2012].
In 4R-tauopathies, Wnt/β-catenin signaling shows disease-specific alterations:
| Disease | Wnt Pathway Activity | Key Findings |
|---------|-----------------|-------------|
| PSP | Reduced | Decreased nuclear β-catenin in basal ganglia[@marchetti2020] |
| CBD | Reduced | Wnt ligand downregulation in motor cortex |
| AGD | Variable | Region-specific changes in entorhinal cortex |
| GGT | Reduced | Oligodendrocyte lineage affected |
| FTDP-17 | Variable | Mutation-dependent effects |
The non-canonical Wnt pathways include Wnt/PCP (planar cell polarity) and Wnt/Ca²⁺ signaling. These pathways are particularly relevant to neuronal polarity, migration, and axonal guidance. In 4R-tauopathies, non-canonical Wnt dysregulation contributes to the selective vulnerability of specific neuronal populations.
Glycogen synthase kinase 3β (GSK3β) is a serine/threonine kinase that plays multiple roles in neuronal function:
GSK3β activity is altered in multiple 4R-tauopathies:
GSK3β activity is elevated in PSP brains, particularly in affected regions including the substantia nigra and globus pallidus. This hyperactivity contributes to:
GSK3β shows region-specific activation in CBD motor cortex and basal ganglia. The pattern differs from PSP, with more pronounced activation in cortical regions. This may reflect the distinct neuroanatomical vulnerability patterns.
GSK3β activation in AGD is more restricted to temporal lobe structures, particularly the entorhinal cortex and amygdala. This correlates with the distribution of argyrophilic grains.
In GGT, GSK3β dysregulation affects both neurons and oligodendrocytes. The oligodendrocyte involvement is unique among 4R-tauopathies and may relate to the glial fibrillary pathology.
GSK3β alterations in FTDP-17 depend on the specific MAPT mutation:
Multiple therapeutic approaches target GSK3β:
| Agent | Mechanism | Development Stage |
|-------|----------|---------------|
| Tideglusib | GSK3β inhibitor | Phase 2 (failed) |
| Lithium | GSK3β inhibitor | Repurposed |
| AR-AA411 | Selective inhibitor | Preclinical |
| Peptide inhibitors | Substrate-specific | Research |
The failure of Tideglusib in clinical trials highlights the complexity of GSK3β inhibition, as complete inhibition disrupts normal neuronal function.
Yes-associated protein (YAP) and Transcriptional coactivator with PDZ-binding motif (TAZ) are the two downstream effectors of the Hippo pathway. They regulate gene expression by interacting with TEAD transcription factors and other partners[@goodridge2018].
Key functions in the nervous system:
YAP/TAZ localization is altered in PSP brainstem nuclei. Nuclear YAP/TAZ decreases in affected neurons, correlating with tau pathology. This reduction may contribute to:
In CBD, YAP/TAZ alterations are most pronounced in motor and premotor cortices. The pattern differs from PSP, with more prominent cytosolic retention. This may relate to the cortical involvement characteristic of CBD.
YAP/TAZ changes in AGD are relatively subtle compared to other 4R-tauopathies, reflecting the more limited regional involvement.
YAP/TAZ signaling shows distinct dysregulation in GGT oligodendrocytes. The glial fibrillary tau pathology affects YAP/TAZ cellular distribution differently than in neuronal tauopathies.
YAP/TAZ alterations in FTDP-17 depend on the specific mutation and brain region. Some MAPT mutations directly or indirectly affect YAP/TAZ nuclear signaling.
The Hippo pathway regulates organ size through a kinase cascade:
| Disease | Hippo Pathway Activity | Neuronal Effects |
|---------|------------------|---------------|
| PSP | Increased (MST1/2 active) | YAP/TAZ exclusion from nucleus |
| CBD | Moderately Increased | Variable by region |
| AGD | Variable | Region-dependent |
| GGT | Altered in glia | Glial dysfunction |
| FTDP-17 | Mutation-dependent | Variable |
The Wnt/β-catenin, GSK3β, YAP/TAZ, and Hippo pathways form an integrated network:
| Pathway Component | PSP | CBD | AGD | GGT | FTDP-17 |
|----------------|-----|-----|-----|-----|----------|
| Wnt/β-catenin | ↓↓ | ↓↓ | ↓ | ↓↓ | variable |
| GSK3β activity | ↑↑ | ↑ | ↑ | ↑ | mutation-dependent |
| YAP/TAZ (nuclear) | ↓↓ | ↓ | ↓ | ↓ (glia) | variable |
| Hippo pathway | ↑↑ | ↑ | - | ↑ (glia) | - |
| Tau pathology | 4R > 3R | 4R > 3R | 4R | 4R (glia) | 4R |
Several therapeutic strategies could benefit multiple 4R-tauopathies:
| Target | Strategy | Pipeline |
|--------|---------|---------|
| GSK3β | Partial inhibition | Preclinical/Phase 2 |
| Wnt pathway activation | Small molecule agonists | Research |
| YAP/TAZ restoration | Activity modulators | Research |
| Tau clearance | Immunotherapies | Phase 2-3 |
The cross-disease comparison reveals both shared mechanisms and disease-specific alterations in Wnt signaling and related pathways:
Understanding the specific pattern of pathway dysregulation in each 4R-tauopathy enables more precise therapeutic targeting.
The following diagram shows the key molecular relationships involving Wnt Signaling in 4R-Tauopathies discovered through SciDEX knowledge graph analysis: